DEFRATAJ (Deferasirox) is indicated for the treatment of chronic iron overload due to frequent blood transfusions in patients with beta-thalassemia major, sickle-cell disease and myelodysplastic syndromes, in line with locally approved prescribing information.

Drop the tablet(s) into 100-200 ml of water, orange juice or apple juice; stir until fully dispersed; drink immediately. Rinse the glass with additional liquid and drink that as well. Take on an empty stomach, at least 30 minutes before food, at the same time daily.

Deferasirox has been used for long-term chelation programmes spanning many years. Long-term use requires regular monitoring of renal function, hepatic function and serum ferritin, with dose adjustments as needed. Severe cutaneous reactions (SJS, TEN, DRESS) are rare but require immediate discontinuation if suspected.

DEFRATAJ dispersible tablets are available in 100 mg, 125 mg, 250 mg, 400 mg and 500 mg.

Yes. Taj Pharma manufactures DEFRATAJ at its WHO-GMP facility in Sarigam, Gujarat, and exports to LATAM, Africa, Asia and CIS markets. Bulk supply, CTD dossiers, private label and tender supply are supported. Send your inquiry via the contact form.

Yes. Module 1-5 CTD dossiers are available on signing of a Confidentiality and Non-Disclosure Agreement (CDA). Country-specific Module 1 documentation and post-approval variation support are part of the supply relationship.

Standard packs are 10 x 10 PVC/PVDC-Aluminium blisters. HDPE bottles and custom pack sizes for tenders or hospital programmes can be quoted on request. Not all pack sizes may be marketed in every territory.

Shelf life is 24-36 months depending on the strength and the regulatory market. Storage condition: below 30 degrees C, protected from moisture, in the original blister.

Deferasirox is approved for pediatric transfusion-dependent iron overload from age 2 years (transfusional) and 6 years (non-transfusional thalassemia) in many markets, with dosing per body weight. Always refer to locally approved prescribing information.

Yes. Avoid simultaneous administration of aluminium-containing antacids, as deferasirox can chelate aluminium. Stagger administration as advised by the prescribing physician.

Report suspected adverse drug reactions to your doctor or directly to your national pharmacovigilance authority. Reports can also be sent to pharmacovigilance@tajpharma.com.

Our export team responds to written inquiries within 24 business hours, with a written quotation, indicative lead time and dossier-availability statement. Business hours: Mon-Sat, 09:30-18:30 IST.